USA flag logo/image

An Official Website of the United States Government

SERODIAGNOSIS OF ULCER

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7976
Program Year/Program:
1988 / SBIR
Agency Tracking Number:
7976
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Allergy Immuno Technologies
1527 Monrovia Ave Newport Beach, CA 92663
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1988
Title: SERODIAGNOSIS OF ULCER
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

SEVERAL SPECIES OF CAMPYLOBACTER ARE KNOWN TO BE ASSOCIATED WITH WIDE RANGE OF HUMAN AND ANIMAL ILLNESSES, MAINLY GASTROENTERITIS, COLITIS, SEPSIS AND URINARY TRACT INFECTIONS. RECENTLY MANY STUDIES CONFIRMED THE CORRELATIONBETWEEN THE PRESENCE OF C. PYLORIDIS (C. PYLORI) ON THE GASTRIC MUCOSA AND DUODENAL ULCERATION. THE MECHANISM BY WHICH THIS ORGANISM INDUCES ULCER IS NOT CLEAR YET BUT IT IS KNOWN THAT COLONIZATION OF C. PYLORIDIS INDUCES LOCAL AND SYSTEMIC IMMUNE RESPONSES. THIS ANTIBODY RESPONSE DIRECTLY CORRELATES WITH HISTOLOGICAL DIAGNOSIS OF CHRONIC OR ACTIVE ULCERS AS WELL AS RENAL TRANSPLANT PATIENTS. THEREFORE, DETECTION OF SPECIFIC ANTIBODIES (IGA, IGG, IGM) AGAINST THIS BACTERIA IS A GOOD INDICATION OF DIAGNOSIS OF GASTRIC ULCER. DURING PHASE I OF THIS STUDY FOUR DIFFERENT ANTIGERS FROM C. PYLORIDIS, C. JEJUNI AND C. COLI WILL BE PREPARED. THESEANTIGENS WILL BE USED FOR DEVELOPMENT OF ELISA AND MEASUREMENT OF ANTIBODIES IN THE PATIENT'S SERA WITH CONFIRMED MEDICAL HISTORY OF ULCER. CROSS REACTIVITY AND SPECIFICITY OF THESE ANTIBODIES WILL BE EXAMINED WITH ANTIGENS OF THREE DIFFERENT SPECIES OF CAMPYLOBECTER (C. FETUS, C. JEJUNI, C. COLI) KNOWN AS A MAJOR CAUSE OF GASTROENTERITIS BUT NOT OF GASTRIC ULCER. ALL ANTIGENS WILLBE ANALYZED BY ELECTROPHORESIS AND SPECIFIC BONDS WILL BE IDENTIFIED BY WESTERN BLOTTING USING POSITIVE C. PYLORIDIS SERA. DURING PHASE II OF THIS STUDY, SPECIES-SPECIFIC ANTIGEN(S) WILL BE PURIFIED AND CHARACTERIZED. MONOCLONAL ANTIBODIES WILL BE PRODUCED FOR HISTOLOGICAL EXAMINATIONS AS WELL AS FOR AFFINITY PURIFICATION OF THESE SPECIFIC ANTIGENS AND THEIR USE IN THE DEVELOPMENT OF SPECIFIC ELISA KITS. FINALLY, AFTER PHASE I FEASIBILITY STUDIES AND PHASE II OF SPECIFIC ELISA KIT PRODUCTION, WE HOPE THAT OUR ELISA TEST WILL REPLACE THE DIFFICULT AND EXPENSIVE PROCEDURES SUCH AS UPPER GASTROINTESTINAL ENDOSCOPY AND BIOPSY, WHICH ARE PRESENTLY REQUIRED TO DEMONSTRATE THE PRESENCE OF C. PYLORIDIS IN THE STOMACH.

Principal Investigator:


0

Business Contact:


7146453703
Small Business Information at Submission:

Allergy Immuno Technologies
1527 Monrovia Ave Newport Beach, CA 92663

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No